Hoch efficienter Vogelgrippe-Impfstoff - Cyber Group Network CGPN mit NEWS! - 500 Beiträge pro Seite
eröffnet am 15.02.06 13:06:50 von
neuester Beitrag 07.08.06 17:52:37 von
neuester Beitrag 07.08.06 17:52:37 von
Beiträge: 16
ID: 1.040.555
ID: 1.040.555
Aufrufe heute: 0
Gesamt: 1.294
Gesamt: 1.294
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 25.04.24, 13:40 | 197 | |
| vor 44 Minuten | 123 | |
| 30.04.24, 19:23 | 88 | |
| vor 1 Stunde | 85 | |
| 30.04.24, 22:31 | 75 | |
| vor 40 Minuten | 54 | |
| 30.04.24, 23:28 | 51 | |
| 30.04.24, 23:55 | 51 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 8,2900 | +4,94 | 228 | |||
| 2. | 2. | 17.899,00 | -1,43 | 204 | |||
| 3. | 3. | 2.291,64 | +0,25 | 73 | |||
| 4. | 4. | 0,9650 | +16,27 | 71 | |||
| 5. | 5. | 67,74 | +1,12 | 67 | |||
| 6. | 6. | 181,03 | -6,71 | 60 | |||
| 7. | 12. | 3,6925 | +0,27 | 27 | |||
| 8. | 8. | 13,988 | +4,74 | 27 |
Feedback
WKN US23244V2088
Quelle: http://biz.yahoo.com/iw/060214/0109838.html
Skystar Bio-Pharmaceutical Developing Avian Influenza (H5N1) Vaccine for Humans and Animals
Tuesday February 14, 11:17 am ET
XIÂ’AN, CHINA--(MARKET WIRE)--Feb 14, 2006 -- Skystar Bio-Pharmaceutical (OTC BB:CGPN.OB - News), a leading Bio-Pharmaceutical Company in China, announced that they are developing the highly efficient Avian Influenza Inactivated Vaccine for poultry, birds and humans.
ADVERTISEMENT
The challenge in making an effective Avian Influenza Vaccine is to solve the issues around the mutation of the actual virus. Once an antigen (vaccine) is introduced to the virus, the virus will mutate rendering the antigen ineffective. For example, a bird or chicken may not show any signs of clinical symptoms after inoculation, but the virus can still hide in its lungs or beak. While hiding, the virus will mutate and become immune to the vaccine. This bird or chicken would now put the rest of the poultry products at risk because it is a "carrier" of a stronger mutated virus.
Skystar is in the process of developing an inactived vaccine. As an inactived vaccine, the Avian Influenza Vaccine merely contains antigen contents but none of the active viral residue, formulated to the latest viral strain. This helps build up immunity in animals and people. This is the same premise in which the annual flu vaccine is based upon.
Current virus technology uses a chicken embryo to breed the virus and produce the vaccine. This technology struggles to keep up with the ever-changing viral strains and is not able to produce enough vaccine to keep up with the demand. Skystar is designing a new technology that is based on a multi-surface cell propagating system. The result is that this process is more controllable and can easily keep up with the virus mutations. Further, this process is more efficient and as a result can be massed produced to keep up with high demand.
Skystar expects to complete their revolutionary vaccine as early as 1st quarter 2007.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company, Ltd. (OTC BB:CGPN.OB - News). Established in 1997, Skystar is a fully GMP certified bio-pharmaceutical company that produces and distributes vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company`s product line consists of more than 60 state-of-the-art products and has over 50 more in the development stage. One of the prominent products in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed existing, strategic sales distribution in 27 provinces and regions in China. The State Ministry of Agriculture in China has authorized the additional construction of a new bio-pharmaceutical facility, which will also conform to GMP standards. For more information about Skystar Bio-Pharmaceutical Company, Ltd.`s innovative products and growth plan, please visit www.xa-tx.com or contact Scott Cramer scramer@cybergroupnetwork.com or (407) 645-4433.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Skystar`s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Contact:
Contact:
Skystar Bio-Pharmaceutical Company, Ltd.
Scott Cramer
Email Contact
(407) 645-4433
--------------------------------------------------------------------------------
Source: The Cyber Group Network Corporation
Quelle: http://biz.yahoo.com/iw/060214/0109838.html
Skystar Bio-Pharmaceutical Developing Avian Influenza (H5N1) Vaccine for Humans and Animals
Tuesday February 14, 11:17 am ET
XIÂ’AN, CHINA--(MARKET WIRE)--Feb 14, 2006 -- Skystar Bio-Pharmaceutical (OTC BB:CGPN.OB - News), a leading Bio-Pharmaceutical Company in China, announced that they are developing the highly efficient Avian Influenza Inactivated Vaccine for poultry, birds and humans.
ADVERTISEMENT
The challenge in making an effective Avian Influenza Vaccine is to solve the issues around the mutation of the actual virus. Once an antigen (vaccine) is introduced to the virus, the virus will mutate rendering the antigen ineffective. For example, a bird or chicken may not show any signs of clinical symptoms after inoculation, but the virus can still hide in its lungs or beak. While hiding, the virus will mutate and become immune to the vaccine. This bird or chicken would now put the rest of the poultry products at risk because it is a "carrier" of a stronger mutated virus.
Skystar is in the process of developing an inactived vaccine. As an inactived vaccine, the Avian Influenza Vaccine merely contains antigen contents but none of the active viral residue, formulated to the latest viral strain. This helps build up immunity in animals and people. This is the same premise in which the annual flu vaccine is based upon.
Current virus technology uses a chicken embryo to breed the virus and produce the vaccine. This technology struggles to keep up with the ever-changing viral strains and is not able to produce enough vaccine to keep up with the demand. Skystar is designing a new technology that is based on a multi-surface cell propagating system. The result is that this process is more controllable and can easily keep up with the virus mutations. Further, this process is more efficient and as a result can be massed produced to keep up with high demand.
Skystar expects to complete their revolutionary vaccine as early as 1st quarter 2007.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company, Ltd. (OTC BB:CGPN.OB - News). Established in 1997, Skystar is a fully GMP certified bio-pharmaceutical company that produces and distributes vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company`s product line consists of more than 60 state-of-the-art products and has over 50 more in the development stage. One of the prominent products in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed existing, strategic sales distribution in 27 provinces and regions in China. The State Ministry of Agriculture in China has authorized the additional construction of a new bio-pharmaceutical facility, which will also conform to GMP standards. For more information about Skystar Bio-Pharmaceutical Company, Ltd.`s innovative products and growth plan, please visit www.xa-tx.com or contact Scott Cramer scramer@cybergroupnetwork.com or (407) 645-4433.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Skystar`s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Contact:
Contact:
Skystar Bio-Pharmaceutical Company, Ltd.
Scott Cramer
Email Contact
(407) 645-4433
--------------------------------------------------------------------------------
Source: The Cyber Group Network Corporation
[posting]20.215.809 von Bourne am 15.02.06 13:06:50[/posting]Wo werden die gehandelt...RE
News kamen gestern ziemlich spät und auf Grund der aktuellen akuten Lage sollte hier kurzfristig bestimmt was gehen. Die Vogelgrippe-Gefahr ist momentan in allen Medien. Hier sind bestimmt schnelle 50% drin.
Thread wurde jetzt schon über 250 mal gelesen, was meint ihr?
Thread wurde jetzt schon über 250 mal gelesen, was meint ihr?
[posting]20.216.579 von RaimondoEntertainment am 15.02.06 13:55:47[/posting]An der OTC. In Deutschland leider nicht.
[posting]20.216.696 von Bourne am 15.02.06 14:02:02[/posting]Finde sie über nordnet gar nicht.
Trading Spotlight
immer diese vogelgrippe-megaimpfstoff-geschichten, ist ja schlimm.
[posting]20.217.569 von Newbeee am 15.02.06 14:49:48[/posting]wenns wirkt und Geld bringt, warum nicht...
Zwischenzeitlich schon mehr als 10% im Plus.
Das war erstmal nichts heute. Warum nicht? RE 
[posting]20.225.441 von RaimondoEntertainment am 15.02.06 21:07:06[/posting]Mehr Publizität für diese Aktie. Wie können wir es erreichen?
RE
RE
[posting]20.227.412 von RaimondoEntertainment am 15.02.06 22:58:49[/posting]Es findet ein Reverse-Split statt. Hat jemand Info? RE
Bin hier Alleinunterhalter. BIn gespannt wie es nach der Pause morgen weitergeht. RE
Antwort auf Beitrag Nr.: 20.227.412 von RaimondoEntertainment am 15.02.06 22:58:49test
auch ein test
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 227 | ||
| 205 | ||
| 73 | ||
| 71 | ||
| 67 | ||
| 59 | ||
| 27 | ||
| 26 | ||
| 24 | ||
| 24 |
| Wertpapier | Beiträge | |
|---|---|---|
| 24 | ||
| 22 | ||
| 22 | ||
| 20 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 |
